Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Almasilate→

Almasilate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
71205-22-6
Molecular formula
Al2H2MgO9Si2
Molecular weight
280.45 g/mol
Drug class
Aluminium-magnesium silicate antacid and adsorbent
Mechanism of action
Neutralises gastric acid and adsorbs selected luminal substances through its mineral surface and acid-neutralising capacity; it acts locally within the gastrointestinal tract.
Indications / reported uses
  • Symptomatic relief of gastric hyperacidity, heartburn and dyspepsia in countries where almasilate-containing oral products are authorised

Sources: NLM MeSH — Almasilate · PubMed — Almasilate antacid · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Aluminium-magnesium silicate antacid and adsorbent

Mechanism of action

Neutralises gastric acid and adsorbs selected luminal substances through its mineral surface and acid-neutralising capacity; it acts locally within the gastrointestinal tract.

General use cases

  • Symptomatic relief of gastric hyperacidity, heartburn and dyspepsia in countries where almasilate-containing oral products are authorised

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Almasilate Environmental Risk Assessment (ERA) (the Almasilate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.